🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Reported risk: Das Produkt enthält Toluol-2,5-diamin, 5-Amino-o-kresol, p-Aminophenol und p-Phenylendiamin (PPD) (Messwerte: 0,2 %, 0,8 %, 4,1 % bzw. 2,7 %) mit einem unzureichenden Kupplungsmittel. Toluol-2,5-diamin, 5-Amino-o-kresol und ungekoppeltes p-Aminophenol und PPD sind extreme Hautsensibilisierungsmittel und können allergische Kontaktdermatitis auslösen. Darüber hinaus kann Toluol-2,5-diamin Krebs verursachen, ist mutagen und kann die Fruchtbarkeit beeinträchtigen. Das Produkt entspricht nicht der Kosmetik-Verordnung.
Action taken by the authority
Type of economic operator to whom the measure were ordered
Retailer
Category of measure
Destruction of the product
Date of entry into force
28/03/2022
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): Brown Henna
Risk Description (original English): The product contains Toluene-2,5-Diamine, 5-Amino-o-cresol, p-aminophenol and p-phenylenediamine (PPD)(measured values: 0.2%, 0.8%, 4.1% and 2.7%, respectively) with an insufficient coupling agent. Toluene-2,5-Diamine, 5-Amino-o-cresol,, and uncoupled p-aminopohenol and PPD are extreme skin sensitisers and can trigger allergic contact dermatitis. Furthermore, Toluene-2,5-Diamine may cause cancer, is mutagenic and might affect fertility.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.